>>Description of the research protocol "GAINED"

Randomized Phase III Study Using a Pet-driven Strategy and Comparing GA101 OR Rituximab Associated to a Chemotherapy Delivered Every 14 Days (ACVBP or CHOP) in DLBCL CD20+ Lymphoma Untreated Patients From 18 to 60 Presenting With 1 or More Adverse Progno
Phase III study| Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Hémato-onco
Brugmann identifier : GAINED
EudraCT identifier : 2011-005851-15
ClinicalTrials.gov identifier : NCT01659099


Involved department : Hemato-oncology
Principal investigator : Efira/Nifosi
Sponsor : LYSARC
Contact : Clinical Research Unit

>This protocol was approved by the UCL St Luc ethics committee.